Athira Pharma Inc (ATHA)

[Whalatane]

The Trade: Athira Pharma, Inc. (ATHA) Director Joseph Edelman acquired a total of 605,686 shares at an average price of $2.42. To acquire these shares, it cost around $1.46 million.
What's Happening: Athira Pharma (ATHA), last month, announced results from SHAPE Phase 2 clinical trial of fosgonimeton for the treatment of Parkinson's disease dementia and dementia with Lewy Bodies.
What Athira Pharma Does: Athira Pharma Inc (ATHA) is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration.

Kiwi